Notably, CB2 agonists, such as celastrol, have recently also been suggested as an anti-fibrotic drug in renal fibrosis [199,200] and therefore, it will be important to rule out a pro-fibrotic effect of CB2 antagonists before considering such drugs for RCC treatment. This evidence concerns the gene CNR2 and renal cell carcinoma.